| Molecule | Cat. No. | Product Name | Espèce | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| GM-CSF | HOT GMF-H4214 | Human GM-CSF Protein, premium grade | Human | HEK293 | ![]() | MALSSDS-PAGE | $235.00 20ug | ||
| GM-CSF | HOT GMF-M5211 | Mouse GM-CSF Protein, Tag Free | Mouse | HEK293 | ![]() | SDS-PAGE | $165.00 20ug | ||
| GM-CSF | HOT GMP-GMFH28 | GMP Human GM-CSF Protein | Human | HEK293 | ![]() | SDS-PAGE | $510.00 50ug | ||
| GM-CSF | Human GM-CSF Protein, Research Grade | Human | HEK293 | ![]() | MALSSDS-PAGE | $199.00 20ug | |||
| GM-CSF | Biotinylated Human GM-CSF Protein, epitope tag free, ultra sensitivity (primary amine labeling) | Human | HEK293 | ![]() | SDS-PAGE | $300.00 25ug | |||
| GM-CSF | AvitagAIDD‑Ready GMF-H82E3 | Biotinylated Human GM-CSF Protein, His,Avitag™ (HPLC verified) | Human | HEK293 | ![]() | HPLCSDS-PAGE | $300.00 25ug |
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Otilimab | MOR-04357; GSK-3196165; GSK-165; MOR-103 | Phase 3 Clinical | University Of Melbourne | Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Multiple Sclerosis; Osteoarthritis; Severe Acute Respiratory Syndrome; Spondylarthritis; Stomach Neoplasms | Details |
| Plonmarlimab | TJM-2; TJ-003234; TJ-003234RAR101 | Phase 3 Clinical | I-Mab Biopharma Co Ltd | Arthritis, Gouty; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Lymphohistiocytosis, Hemophagocytic; Macrophage Activation Syndrome | Details |
| Gemogenovatucel-T | IND-14205 | Phase 3 Clinical | Gradalis Inc | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Colonic Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Liver Neoplasms; Lung Neoplasms; Melanoma; Ovarian Neoplasms; Peritoneal Neoplasms; Sarcoma, Ewing; Uterine Cervical Neoplasms; Uterine Neoplasms | Details |
| PBI-1402 | PBI-1402 | Phase 2 Clinical | Prometic Life Sciences | Anemia | Details |
| Pexastimogene devacirepvec | TG-6006; JX-594 | Phase 2 Clinical | National Cancer Institute, Regeneron Pharmaceuticals Inc, Samsung Medical Center & Samsung Electronics Devices Llc, Sillajen Inc | Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colorectal Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphoma; Melanoma; Neoplasm Metastasis; Neoplasms; Neuroblastoma; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Wilms Tumor | Details |
| Breast cancer therapy (BriaCell Therapeutics) | Phase 2 Clinical | Briacell Therapeutics Corp | Breast Neoplasms; Metastatic breast cancer | Details | |
| Gimsilumab | MORAb-022; KIN-1901 | Phase 2 Clinical | Morphotek Inc | Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Inflammation; Rheumatic Diseases | Details |
| MEDI-5395 | MEDI-5395; MEDI5395 | Phase 1 Clinical | Medimmune | Solid tumours | Details |
| BBM-C101 | Phase 1 Clinical | Belief BioMed Inc | Squamous Intraepithelial Lesions of the Cervix | Details |